A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010–2012

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 9, 2015, Pages 1639-1644

  Maschmeyer, Georg ^a   Mügge, Lars Olof ^b   Kämpfe, Dietrich ^c   Kreibich, Ute ^d   Wilhelm, Stephan ^e   Aßmann, Michael ^f   Schwarz, Maik ^g   Kahl, Christoph ^h,i   Köhler, Susanne ^j   Grobe, Norbert ^k   Niederwieser, Dietger ^l  

^a KLINIKUM ERNST VON BERGMANN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c Praxis für Hämatologie und Onkologie   (Germany)

^d Heinrich Braun Klinikum Zwickau gGmbH   (Germany)

^e Internistische Gemeinschaftspraxis   (Germany)

^f MVZ Elblandpolikliniken GmbH   (Germany)

^g Paracelsus Medizinisches Versorgungszentrum Schöneck I   (Germany)

^h Klinikum Magdeburg gGmbH   (Germany)

ⁱ ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^j HELIOS Kreiskrankenhaus Gotha Ohrdruf   (Germany)

^k Dietrich Bonhoeffer Klinikum   (Germany)

^l UNIVERSITY HOSPITAL LEIPZIG   (Germany)

more..

Author keywords

Chemotherapy; NEC; NET; Neuroendocrine carcinoma; Somatostatin

Indexed keywords

CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLIC ACID; GEMCITABINE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; TEMOZOLOMIDE; TOPOTECAN; TREOSULFAN;

ARTICLE; BLADDER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; DISEASE SEVERITY; FOREGUT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER; LUNG; MAJOR CLINICAL STUDY; MIDGUT; MONOTHERAPY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROSTATE; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TUMOR LOCALIZATION; CANCER GRADING; CLINICAL TRIAL; FEMALE; GERMANY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEUROENDOCRINE TUMORS; PATHOLOGY;

FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEUROENDOCRINE TUMORS; RETROSPECTIVE STUDIES;

EID: 84939265864     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1954-x     Document Type: Article

References (23)

1. AJCC (2010) Exocrine and endocrine pancreas. In: Edge SB, Byrd, Compton CC et al (eds) AJCC cancer staging manual, 7th edn. Springer, New York, pp 241–249
2. Hainsworth JD, Spigel DR, Litchy S, Greco FA (2006) Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network study. J Clin Oncol 24:3548–3554
3. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gönen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O’Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J (2010) Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34:300–313
4. Klöppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, Scarpa A, Scoazec JY, Wiedenmann B, Papotti M, Rindi G, Plöckinger U (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology 90:162–166
5. Mitry E, Rougier P (2001) The treatment of undifferentiated neuroendocrine tumors. Crit Rev Oncol Hematol 37:47–51
6. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P (1999) Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351–1355
7. Moertel CG, Kvols LK, O’Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232
8. National Comprehensive Cancer Network (NCCN) (2014) Clinical practice guidelines in oncology: neuroendocrine tumors (Version 1.2015). www.nccn.org. Last access 20 Dec 2014
9. Oberg K, Castellano D (2011) Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev 30(Suppl 1):3–7
10. Olsen IH, Langer SW, Jepsen I, Assens M, Federspil B, Hasselby JP, Hansen CP, Kjaer A, Knigge U (2012a) First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience. Acta Oncol 51:97–100
11. Olsen IH, Sorensen JB, Federspil B, Kjaer A, Hansen CP, Knigge U, Langer SW (2012b) Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. Sci World J 2012:170496
12. Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B, Salazar R, Barcelona Consensus Conference participants (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176
13. Ploeckinger U, Kloeppel G, Wiedenmann B, Lohmann R, representatives of 21 German NET Centers (2009) The German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors. Neuroendocrinology 90:349–363
14. Ramella Munhoz R, de Mendonça Rego JF, de Celis Ferrari AR, Braghiroli MI, Mendonça Bariani G, Hoff PM, Perego Costa F, Flesch Pfiffer TE, Riechelmann R (2013) Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas. Rare Tumors 5:e39
15. Rindi G, Wiedenmann B (2011) Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol 8:54–64
16. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B, European Neuroendocrine Tumor Society (ENETS) (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401
17. Rindi G, Klöppel G, Couvelard A, Komminoth P, Körner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451:757–762
18. Smith J, Reidy-Langunes D (2013) The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas. Semin Oncol 40:100–108
19. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24:152–160
20. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK (2010) The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 39:799–800
21. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K (2011) Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 117:4617–4622
22. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072
23. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O’Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B (2010) Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28:69–76